The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Vallon Pharmaceuticals, which is developing abuse-deterrent prescription drugs for CNS disorders, raised $18 million by offering 2.25 million shares at $8, the low end of the range of $8 to $10. The company sold 580,000 more shares on the offering that...read more
Vallon Pharmaceuticals, a biopharma developing abuse-deterrent prescription drugs for CNS disorders, announced terms for its IPO on Thursday.
The Philadelphia, PA-based company plans to raise $15 million by offering 1.7 million shares at a price range of $8...read more
Vallon Pharmaceuticals, a biopharmaceutical company developing abuse-deterrent prescription drugs for CNS disorders, filed on Friday with the SEC to raise up to $17 million in an initial public offering. The company's clinical-stage product currently under...read more
US IPO Weekly Recap: IPO frenzy brings the year’s largest deal and biggest pop in a 17 IPO week
The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Abuse-deterrent drug developer Vallon Pharmaceuticals prices $18 million IPO at $8 low end
Vallon Pharmaceuticals, which is developing abuse-deterrent prescription drugs for CNS disorders, raised $18 million by offering 2.25 million shares at $8, the low end of the range of $8 to $10. The company sold 580,000 more shares on the offering that...read more
Micro-cap drug developer Vallon Pharmaceuticals sets terms for $15 million IPO
Vallon Pharmaceuticals, a biopharma developing abuse-deterrent prescription drugs for CNS disorders, announced terms for its IPO on Thursday. The Philadelphia, PA-based company plans to raise $15 million by offering 1.7 million shares at a price range of $8...read more
CNS pharmaceutical developer Vallon Pharmaceuticals files for a $17 million IPO
Vallon Pharmaceuticals, a biopharmaceutical company developing abuse-deterrent prescription drugs for CNS disorders, filed on Friday with the SEC to raise up to $17 million in an initial public offering. The company's clinical-stage product currently under...read more